Loading...
TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells
Toll-like receptor 3 (TLR3) agonists have been extensively used as adjuvants for anticancer vaccines. However, their immunostimulatory effects and precise mechanisms of action in the presence of antineoplastic monoclonal antibodies (mAbs) have not yet been evaluated. We investigated the effect of TL...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Landes Bioscience
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3716757/ https://ncbi.nlm.nih.gov/pubmed/23894722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.24677 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|